Cost-Effectiveness and Budget Impact of High-Dose Trivalent Influenza Vaccine Efluelda® in Older Adults: A Greek Healthcare System Perspective
Author(s)
Panagiotis Rigopoulos, MSc1, Apostolos Stratopoulos, MSc, PhD1, Gerald Moncayo, Phd2, Kallia Mortaki, MSc1, Isidoros Kougioumtzoglou, MBA3.
1Vianex sa, Athens, Greece, 2Sanofi, Lyon, France, 3University of West Attica, Athens, Greece.
1Vianex sa, Athens, Greece, 2Sanofi, Lyon, France, 3University of West Attica, Athens, Greece.
OBJECTIVES: Older adults are disproportionately affected by seasonal influenza, experiencing the highest rates of severe complications, hospitalizations, and mortality. High-dose (HD) influenza vaccines, such as Efluelda®, have demonstrated superior clinical effectiveness in this vulnerable population. However, robust economic evaluations tailored to the Greek healthcare context are currently lacking. This study aims to assess the cost-effectiveness and budget impact of the HD trivalent influenza vaccine (Efluelda®) compared to standard-dose vaccines in adults aged 65 and older, as recommended by the national immunization calendar in Greece.
METHODS: The model that was developed relies on a decision tree structure with a lifetime horizon to compare Efluelda® to standard of care (standard-dose influenza vaccines). The model adopted the perspective of the Greek public payer, utilizing clinical-epidemiological data and direct medical costs, which derived from Greek relevant published studies, national statistics data and Greek DRG tariffs. Deterministic sensitivity analysis (DSA), probabilistic sensitivity analysis (PSA), and threshold analyses were performed to test model robustness and pricing flexibility. A complementary budget impact analysis estimated system-wide savings associated with the introduction of Efluelda®.
RESULTS: The base-case analysis showed an ICER of €10,274 per QALY and €8,109 per LY gained, with a QALY gain of 0.000832 per vaccinated individual. Threshold analysis confirmed cost-effectiveness at the level of €10,000/QALY threshold with its current price. PSA showed 59% probability of cost-effectiveness at the Greek GDP per capita (€25,300) and 100% at €30,000. Budget impact analysis estimated €13 million in net savings, mainly from reduced respiratory-related hospitalizations (€12.2 million).
CONCLUSIONS: Efluelda® offers a cost-effective and potentially cost-saving intervention for influenza prevention in Greek adults aged 65 and older. Its adoption could substantially reduce the burden on the healthcare system, particularly by averting respiratory complications. These findings support the inclusion of Efluelda® in national vaccination strategies.
METHODS: The model that was developed relies on a decision tree structure with a lifetime horizon to compare Efluelda® to standard of care (standard-dose influenza vaccines). The model adopted the perspective of the Greek public payer, utilizing clinical-epidemiological data and direct medical costs, which derived from Greek relevant published studies, national statistics data and Greek DRG tariffs. Deterministic sensitivity analysis (DSA), probabilistic sensitivity analysis (PSA), and threshold analyses were performed to test model robustness and pricing flexibility. A complementary budget impact analysis estimated system-wide savings associated with the introduction of Efluelda®.
RESULTS: The base-case analysis showed an ICER of €10,274 per QALY and €8,109 per LY gained, with a QALY gain of 0.000832 per vaccinated individual. Threshold analysis confirmed cost-effectiveness at the level of €10,000/QALY threshold with its current price. PSA showed 59% probability of cost-effectiveness at the Greek GDP per capita (€25,300) and 100% at €30,000. Budget impact analysis estimated €13 million in net savings, mainly from reduced respiratory-related hospitalizations (€12.2 million).
CONCLUSIONS: Efluelda® offers a cost-effective and potentially cost-saving intervention for influenza prevention in Greek adults aged 65 and older. Its adoption could substantially reduce the burden on the healthcare system, particularly by averting respiratory complications. These findings support the inclusion of Efluelda® in national vaccination strategies.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE223
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis
Disease
Geriatrics, Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory), Vaccines